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Abstract
Dengue is a major cause of morbidity in Puerto Rico and is well-known to its physicians. Early case identification and timely
initiation of treatment for patients with severe dengue can reduce medical complications and mortality. To determine
clinical management and reporting practices, and assess knowledge of dengue and its management, a survey was sent to
2,512 physicians with a medical license in Puerto Rico. Of the 2,313 physicians who received the survey, 817 (35%)
completed the questionnaire. Of the respondents, 708 were currently practicing medicine; 138 were board certified (Group
1), 282 were board eligible (Group 2), and 288 had not finished residency (Group 3). Although respondents clinically
diagnosed, on average, 12 cases of dengue in the preceding three months, 31% did not report any suspected cases to
public health officials while about half (56%) reported all cases. Overall, 29% of respondents correctly identified early signs
of shock and 48% identified severe abdominal pain and persistent vomiting as warning signs for severe dengue with the
proportion of correct respondents highest in Group 1. Reportedly about sixty percent (57%) appropriately never give
corticosteroids or prophylactic platelet transfusions to dengue patients. One third (30%) of respondents correctly identified
administration of intravenous colloid solution as the best treatment option for dengue patients with refractory shock and
elevated hematocrit after an initial trial of intravenous crystalloids, and nearly one half (46%) correctly identified
administration of a blood transfusion as the best option for dengue patients with refractory shock and decreased
hematocrit after a trial of intravenous crystalloids. Even though dengue has been endemic in Puerto Rico for nearly 4
decades, knowledge of dengue management is still limited, compliance with WHO treatment guidelines is suboptimal, and
underreporting is significant. These findings were used to design a post graduate training course to improve the clinical
management of dengue.
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Introduction
Dengue is a mosquito-borne disease caused by any one of four
dengue virus (DENV) types -1, -2, -3, and -4. Each DENV is
capable of causing the full spectrum of disease from an
asymptomatic infection to severe, life-threatening illness including
dengue hemorrhagic fever (DHF) and dengue shock syndrome
(DSS) [1]. Dengue is a major public health problem throughout
the tropics and subtropics worldwide. There is currently no
vaccine available to prevent dengue and vector control measures
to prevent DENV transmission have not been sustainable or
effective [2,3]. Once a person has dengue, there is no licensed
antiviral medication to treat or prevent severe manifestations of
the disease. However, implementation of other secondary preven-
tion measures including timely identification of dengue cases and
initiation of intensive supportive treatment can reduce case fatality
rates from 10% to less than 1% among severe cases [4–8].
The incidence and severity of dengue has been steadily
increasing over the last three decades throughout much of South
and Central America, Mexico, and the Caribbean including
Puerto Rico [9]. Even though dengue has been endemic in Puerto
Rico since the late 1960s [10], how physicians identify, diagnose,
and report patients with suspected dengue is not well known.
Similarly, even though the severity of dengue has increased with
every subsequent dengue outbreak in Puerto Rico since 1994 [11],
little is known about clinical management practices for dengue on
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the island. However evidence from fatal dengue case review
suggests that treatment practices in Puerto Rico may differ from
the World Health Organization (WHO) guidelines [12,13] even
though efforts to educate physicians concerning dengue manage-
ment based on the most current guidelines had been performed
from the late 1980s to the early 1990s and then intermittently with
each subsequent outbreak [14]. To better understand diagnostic,
treatment and reporting practices, we conducted a survey among
physicians practicing in Puerto Rico in 2007–2008. Findings were
used to develop a post graduate training course on the clinical
management of dengue to minimize dengue morbidity and
mortality, and to improve reporting of suspected dengue cases in
Puerto Rico so that we can better understand the true burden of
disease.
Materials and Methods
In 2007, there were 8,051 physicians residing in Puerto Rico
who had a Drug Enforcement Administration (DEA) number and
active license to practice medicine in Puerto Rico, according to the
Puerto Rico Department of Health (PRDH) (Figure 1). Physicians
who were unlikely to diagnose and treat patients with dengue were
excluded from the list of 8,051 physicians, including surgeons,
pathologists, radiologists, allergists, dermatologists, endocrinolo-
gists, geneticists, nephrologists, neurologists, ophthalmologists,
otolaryngologists, oncologists, psychiatrists, rheumatologists, and
sports medicine physicians. The remaining 5,997 physicians
consisted of 5,635 generalists involved in primary and emergency
care of dengue patients (e.g., general practitioners, family
practitioners, pediatricians, emergency department physicians,
obstetricians and gynecologists, and internal medicine physicians)
and 362 specialists, most notably cardiologist and pulmonologists
who are most likely to work in intensive care units in Puerto Rico,
and intensive care physicians.
To determine physicians’ knowledge of how to diagnose and
treat dengue according to the 1997 WHO guidelines and to assess
their treatment and reporting practices, we determined that 1,068
generalists were needed to be 95% confident of being within 63%
of the assumed population proportion of 50%, used because this
value gives the most conservative sample size estimates. We
expected, based on the literature, that there would be a 50% non-
participation rate, and therefore a simple random sample of 2,150
generalists was selected from the 5635 primary care and
emergency medicine physicians. In addition, all 362 specialists
were invited to participate. This survey underwent institutional
review at the Centers for Disease Control and Prevention (CDC)
and was determined to be public health practice and not research;
as such, Institutional Review Board approval was not required.
We sent a 37-item questionnaire, a personalized cover letter
explaining the purpose of the survey, and a pre-addressed, prepaid
return envelope to the 2,512 physicians in October of 2007
(Figure 1). One hundred and ninety-nine questionnaires were
returned because of an inaccurate mailing address. Three weeks
after the initial mailing, a reminder postcard was sent. A second
copy of the questionnaire and a pre-addressed, prepaid return
envelope was sent in mid-January 2008, and a second reminder
postcard was sent in early February 2008. No incentives were
given for participating.
The questionnaire, which was pilot tested among a small,
diverse group of physicians practicing in Puerto Rico, asked for
demographic information including age, sex, and training history
(e.g., location of medical school and year of graduation, location of
residency training, and whether or not they were board certified or
finished a residency program). Further, physicians were asked
whether or not they were currently practicing medicine, the
location and type of healthcare facility of their current practice,
and the average number of suspected dengue patients seen per
week. Respondents who reported that they were no longer
practicing medicine or did not see patients with dengue were
excluded from the final analysis. Respondents who were currently
practicing were asked questions about the clinical and laboratory
diagnosis of dengue, and how frequently they report suspected
dengue cases. Practicing respondents were also asked about their
hospital referral criteria for patients suspected of having dengue,
and to identify warning signs for severe dengue and early signs of
shock. The questionnaire also asked about specific treatment
practices including use of corticosteroids, prophylactic platelet
transfusions, and intravenous immune globulin for patients
suspected of having dengue, and knowledge of when to use
intravenous colloid solutions and blood products in dengue
patients with refractory shock after an initial trial of an intravenous
crystalloid. A copy of the questionnaire is available upon request.
A pre-specified analysis of management practices and knowl-
edge of dengue was conducted by respondent level of training;
groups included board-certified physicians (Group 1), residency
trained physicians without board-certification (Group 2), and
physicians who did not complete residency training and were
therefore not qualified to take the Board examination (Group 3).
Throughout, point estimates, 95% confidence intervals (CI), and
statistical tests were computed accounting for the sampling design
(stratified, simple random sample) and incorporating a finite
population correction [15]. Comparisons among groups were
made using a chi-squared test for categorical data accounting for
the survey design and using the Rao-Scott adjustment [16].
Simultaneous CIs for the differences among group proportions
were adjusted using the Bonferroni adjustment. Group means
were compared using the likelihood ratio test with the Rao-Scott
adjustment and accounting for the sampling design [16].
In order to assess the internal and external validity of the
survey’s results, we evaluated the questionnaires for completeness
and recorded those questionnaires that were discarded and the
reasons for doing so. Response proportions were compared to
available population proportions for sex and physician location
(San Juan metro area or Ponce), and these were assessed using a
Author Summary
Dengue is a major cause of morbidity in Puerto Rico and is
well-known to its physicians. Early case identification and
timely initiation of treatment for patients with severe
dengue can reduce medical complications and mortality.
We conducted a survey among physicians who practice in
Puerto Rico to determine clinical management and
reporting practices and assess knowledge of dengue and
its management. We found that although respondents
clinically diagnosed, on average, 12 cases of dengue in the
preceding three months, one third did not report any
suspected cases to public health officials while about half
reported all cases. We found that knowledge of dengue
management was limited and compliance with WHO
treatment guidelines was not optimal. As other dengue
endemic countries have reported similar findings, a
sustained continuing medical education training initiative
may be necessary to improve case detection and clinical
management even in countries where the disease is
common. Our findings were used to design a postgraduate
training course to improve the clinical management of
dengue.
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Figure 1. Study population. The number of physicians residing in Puerto Rico who had an active license to practice medicine is shown in the first
box. A random sample of 2,512 physicians who were likely to diagnose and treat dengue patients were sent a survey as shown in the second box. Of
the 2,313 physicians who received the survey (third box), 817 completed the questionnaire (fourth box). Of the 817 respondents, 109 were excluded
because they were no longer practicing medicine (fifth box). For the analysis, the 708 physicians were separated into three mutually exclusive groups:
board certified, residency training only, and no residency training.
doi:10.1371/journal.pntd.0003192.g001
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chi-squared goodness-of-fit test accounting for the sampling design
[16]; other demographic information was unavailable on a
population level to provide reference for evaluation. All data
analyses were conducted using STATA version 10 and the survey
package in R [15,17].
In the tables and text we report both the raw counts of the
numbers of respondents in the stated categories and the relevant
total numbers of respondents. We also report estimates of
population proportions and means based on survey data analysis,
a statistical method which incorporates weighting, so these
estimates may not match crude proportions calculated from the
values reported. All proportions and means are such survey-based
population estimates. To ease presentation, we do not include CIs
in the text below when these can be found in the tables.
Results
Of the total 2,313 physicians who received the survey, 817
(35.3%) completed the questionnaire (Figure 1). Of the 817
respondents, 109 were excluded from the final analysis because
they reported that they were no longer practicing medicine. The
remaining 708 physicians were separated into three mutually
exclusive groups: Group 1, board certified (n = 138); Group 2,
residency only (n = 282); and Group 3, no residency (n = 288)
(Table 1). The majority of respondents were male, more than fifty
years old, and reported attending medical school outside of Puerto
Rico, mostly notably in the Dominican Republic, Spain, or
Mexico. Respondents reported practice locations throughout the
island. The proportion of male respondents (62%) differed
significantly, if not dramatically, from the reported physician
population proportion of males (69%) (p = 0.01), while the rates for
physician office location did not (San Juan metro area, p = 0.42;
Ponce, p = 0.48).
Respondent characteristics varied by group (Table 1). Groups 1
and 2 had roughly similar age distributions, but a higher
proportion of Group 1 respondents attended medical school in
Puerto Rico and reportedly practiced medicine in the San Juan
Metro Area when compared to Group 2 or 3 respondents. Group
3 respondents were more likely than those from Group 1 and 2 to
be older, trained in Dominican Republic, and practicing outside of
the San Juan Metro Area.
Respondents clinically diagnosed on average 12 cases of dengue
in the three months before participating in the survey (Table 2).
Slightly more than half (56%) of all respondents stated that they
report all clinically suspected dengue cases to public health officials
while about one third (31%) said that they do not report any
suspected cases. During this same time period, respondents
requested dengue diagnostic testing for only three cases on
average. Few respondents were able to correctly identify labora-
tory assays used to diagnose acute DENV infections, however, this
varied significantly by group with Group 1 respondents being most
likely to respond correctly (Table 3).
Table 1. Physician characteristics overall and by level of training group.
All responders (N=817) Group 1 (N=138) Group 2 (N=282) Group 3 (N=288) (p-value)
Characteristic No.: Estimated Percentage* (95% CI)
Male gender 500: 64(61,67) 81: 58(50,66) 173: 64(58,69) 178: 65(60,71) 0.42
Age, years
21–40 93: 11(9,14) 21: 15(10,22) 32: 11(8,15) 40: 14(11,18)
41–50 220: 27(24,30) 51: 41(33,50) 94: 34(29,39) 65: 23(19,28)
51–60 277: 34(31,38) 49: 37(29,45) 101: 36(31,41) 108: 38(33,43)
61+ 217: 27(24,30) 15: 8(5,11) 53: 19(15,24) 71: 25(21,30) ,0.001
Year Graduated
1990s+ 154: 20(17,23) 29: 21(15,29) 56: 21(17,26) 64: 23(19,28)
1980s 305: 40(37,43) 63: 53(44,61) 115: 43(38,49) 113: 41(36,47)
1970s 214: 27(24,30) 36: 22(17,30) 70: 26(21,31) 77: 28(23,33)
Prior to 1970 103: 13(11,15) 7: 4(2,6) 27: 10(7,14) 19: 7(5,10) 0.14
Medical School
Puerto Rico 271: 30(27,33) 107: 81(75,86) 101: 36(31,41) 30: 10(7,14)
Dominican Republic 216: 29(27,32) 7: 4(2,9) 71: 25(21,30) 125: 43(38,49)
Spain 166: 22(19,24) 6: 3(2,6) 59: 21(17,21) 63: 22(18,27)
Mexico 110: 14(12,17) 7: 5(2,10) 40: 14(11,18) 58: 20(16,25)
USA 19: 2(1,3) 5: 3(1,5) 3: 1(0.4,3) 3: 1(0.4,3)
Other 35: 4(3,6) 6: 4(2,8) 8: 3(1,5) 9: 3(2,6) ,0.001
Practice Site
San Juan Metro 310: 43(39,46) 80: 58(49,66) 131: 47(41,52) 99: 35(30,40)
Ponce Area 42: 6(5,8) 8: 7(4,14) 23: 8(6,12) 11: 4(2,7)
Other 346: 51(47,54) 48: 35(27,43) 126: 45(39,50) 172: 61(56,66) ,0.001
* Percentages incorporate survey design weights, and thus may not equal the crude proportions. Fewer than 12% of respondents failed to answer any individual
question; the denominator includes only those who answered the question in order to give the most conservative estimate.
doi:10.1371/journal.pntd.0003192.t001
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Methods used to clinically diagnose patients with dengue did
not differ by group (Table 3). The majority (92%) reported always
using criteria consistent with the 1997 WHO case definition to
identify suspected dengue cases while a similar proportion (96%)
reportedly always use platelet count or white cell count (89%) to
identify suspected cases. Less than one quarter (19%) of all
respondents reported using the tourniquet test to identify
suspected dengue cases.
Knowledge of warning signs for severe dengue and early signs of
shock was low overall and knowledge varied by group (Table 3).
One-third (29%) of respondents overall correctly identified
tachycardia and delayed capillary refill as early signs of shock,
and this proportion increased from Group 3 to Group 1. One half
(48%) of all respondents were able to correctly identify severe
abdominal pain and persistent vomiting as warning signs with a
higher proportion of Group 1 respondents than Group 2 or 3
Table 2. Clinical and laboratory diagnosis and reporting of dengue patients.
Overall (n =708) Group 1 (n=138) Group 2 (n=282) Group 3 (n =288) Overall p-value
Number of
diagnoses in
last 3 months
Estimated Mean
(95% CI)
Clinical diagnoses 11.5(10.3,12,7) 10.9(8.1,13.7) 11.5(9.7,13.3) 11.6(9.8,13.5) 0.93
Laboratory diagnoses 3.0(2.4,3.6) 2.2(1.4,2.9) 2.5(1.7,3.2) 4.0(2.8,5.2) 0.02
Number of suspected
cases reported
Number: Estimated
Proportion (95% CI) Overall p-value
All cases 368: 56(52,50) 62: 46(37,54) 156: 60(54,65) 150: 55(50,61)
Some cases 85: 13(10,15) 21: 20(13,28) 28: 11(7,15) 36: 13(10,17)
No cases 207: 31(28,35) 44: 35(27,44) 77: 30(25,35) 86: 32(27,37) 0.13
doi:10.1371/journal.pntd.0003192.t002
Table 3. Knowledge of early signs of shock and warning signs for severe dengue, how to make laboratory diagnosis and reported
criteria for referral to hospital.*
Overall (n = 708) Group 1 (n =138) Group 2 (n =282) Group 3 (n=288) p-value
No./Total No. Who Answered: Estimated Percentage (95% CI)
Clinical diagnosis (% who always use):
Use 1997 WHO case definition{ 624/678: 92(90,94) 15/128: 88(80,93) 255/273: 93(90,96) 254/277: 92(88,94) 0.20
Use platelet count 654/685: 96(94,97) 122/130: 95(90,97) 265/278: 95(92,97) 267/277: 96(94,98) 0.66
Use white cell count 600/680: 89(86,91) 111/130: 86(80,91) 245/275: 89(85,92) 244/275: 89(84,92) 0.76
Use tourniquet test 119/626: 19(16,22) 19/126: 11(8,16) 48/253: 19(5,24) 52/247: 21(17,26) 0.07
Knowledge (% who correctly identified):
Tachycardia & delayed capillary
refill as early sign of shock
215/708: 29(26,33) 54/138: 38(30,46) 101/282: 36(31,41) 60/288: 21(17,26) ,0.001
Severe abdominal pain and persistent
vomiting as warning signs
347/708: 48(44,51) 86/138: 63(55,71) 132/282: 47(41,52) 129/288: 45(39,50) 0.003
All warning signs listed{ 181/665: 26(23,30) 44/126: 35(27,44) 75/266: 28(23,33) 62/274: 23(18,28) 0.04
All laboratory tests used to
diagnose acute cases of dengue
40/578: 6(4,7) 21/119: 15(10,22) 16/232: 7(4,11) 3/227: 1(0.5,4) ,0.001
Hospital Referral Criteria (% who refer for):
Criteria consistent with 1997 Guidelines 216/677: 31(28,34) 47/125: 33(25,41) 101/275: 37(31,42) 68/277: 25(20,30) 0.002
Minor bleeding without shock or
hemoconcentration
457/677: 68(64,71) 74/125: 58(49,67) 189/275: 69(63,74) 194/277: 70(65,75) 0.02
Platelet count #100,000 without bleeding,
hemoconcentration, or shock
213/677: 32(28,35) 32/125: 24(17,32) 106/275: 38(33,44) 75/277: 27(22,32) ,0.001
* Percentages incorporate survey design weights, and thus may not equal the crude proportions. Fewer than 12% of respondents failed to answer any individual
question; the denominator includes only those who answered the question in order to give the most conservative estimate.
{1997 WHO case definition defined dengue as an acute febrile illness of 2 to 7 days duration with 2 or more of the following: headache, retro-orbital pain, myalgia,
arthralgia, rash, hemorrhagic manifestations, leucopenia. Warning signs include: severe abdominal pain, persistent vomiting, cold and clammy skin/extremities,
narrowing pulse pressure, hypotension, change in mental status (e.g., irritability, lethargy).
doi:10.1371/journal.pntd.0003192.t003
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respondents being able to do so. Ability to identify all warning
signs from a list was low (26%), with Group 1’s ability significantly
higher than Groups 2 and 3 (p = 0.04).
About one third (31%) of respondents reportedly use hospital
referral criteria consistent with the 1997 guidelines (Table 3). Not
all respondents reportedly refer suspected dengue patients who
have a hemorrhagic manifestation; 68% of all respondents refer
suspected dengue patient with minor bleeding (e.g., epistaxis, gum
bleeding) in the absence of shock or hemoconcentration. About
one third (32%) of all respondents use a platelet count of #
100,000 cells/mm3 in the absence of bleeding, hemoconcentra-
tion, or shock as a criteria for hospital referral.
Knowledge of the WHO treatment guidelines varied among
groups (Table 4). When given the scenario of a suspected dengue
patient with persistent shock and an elevated hematocrit level after
a trial of an intravenous crystalloid solution, one third (30%) of all
respondents correctly responded that they would give the patient
an intravenous colloid. This proportion varied from 39 to 23%
among groups with Group I having the highest proportion of
correct answers. However, a higher proportion of Groups 1 (48%)
and 2 (47%) respondents said that they would give the patient a
vasopressor given this scenario. Given a second scenario where a
suspected dengue patient has persistent shock and a decreasing
hematocrit level after a trial of intravenous crystalloids, about half
(46%) of all respondents correctly identified blood transfusion as
the treatment of choice, and the proportions among the groups
were not statistically significantly different.
Many (57%) of the respondents appropriately never give
corticosteroids to their patients with suspected dengue (Table 4).
The majority (72%) of Group I respondents reportedly do not use
corticosteroids while slightly more than half of Group 2 and 3
respondents reported not giving corticosteroids to their suspected
dengue patients. Likewise, the same proportion (57%) of
respondents correctly does not give prophylactic platelet transfu-
sions, and this practice varied in a similar fashion by group.
Among the 63 respondents who reportedly give prophylactic
platelet transfusions, 41 (65%) individuals stated that their
threshold for giving platelets is between 25,000 and 50,000
cells/mm3, while 22 (35%) gave #20,000 cells/mm3 as their
threshold. The overwhelming majority (92%) of respondents
appropriately do not give intravenous immunoglobulin to their
patients with dengue.
Discussion
This survey demonstrates that knowledge and management of
dengue vary among physicians practicing in Puerto Rico,
particularly between Board-certified physicians and non-Board-
certified physicians, especially those who did not complete
residency training. There were four important findings from this
survey. First, while most reportedly use WHO case definition to
clinically diagnose dengue cases, we found that case reporting to
public health authorities is not optimal and knowledge of
laboratory diagnosis of dengue was poor. Second, many respon-
dents, regardless of their level of training, were unable to identify
early signs of shock and warning signs for severe dengue,
knowledge needed to effectively give anticipatory guidance and
inform triage and referral decisions. Third, reported compliance
with treatment guidelines of dengue patients in refractory shock
was generally low. Fourth, corticosteroids and prophylactic
platelet transfusions were reportedly used by about 40% of
respondents; practices that are not recommended by current or
past treatment guidelines [13,18–20].
While respondents reportedly had clinically diagnosed 12 dengue
cases on average in the preceding three months, about one-third of
respondents did not report any cases to the Puerto Rico Department
of Health and half reported all cases as required by law. Taken
together, these findings suggest that dengue is underreported in
Puerto Rico. This finding is consistent with past studies that
estimated that for every case of suspected dengue reported to the
passive dengue surveillance system (PDSS) in Puerto Rico, ten to 27
cases are not reported, and for every case of dengue hemorrhagic
fever (DHF) reported, 15 DHF cases are not reported [21,22].
Given these findings, it was not surprising to find that few (,6%)
respondents knew which laboratory tests are used to diagnose acute
dengue as they do not routinely report cases to PDSS, a system that
requires submission of a case investigation form and serum sample
for case reporting and free diagnostic testing.
Treatment guidelines for the clinical management of dengue
were first introduced by WHO in 1975 [18] and they were then
updated in 1997 [13] and 2009 [19]. The 1997 WHO guidelines
were translated into Spanish, widely distributed throughout the
Caribbean, and in use when this survey was administered
(October 2007 to February 2008) [20]. Identification of dengue
patients with early signs of shock and warning signs for severe
Table 4. Reported knowledge of and adherence to 1997 World Health Organization treatment guidelines.*
Overall (n =708) Group 1 (n =138) Group 2 (n=282) Group 3 (n =288) p-value
No./Total No. Who Answered: Estimated Percentage (95% CI)
Knowledge (% who would first give):
Intravenous colloid solution for refractory
shock with elevated hematocrit
100/307: 30(26,35) 36/82: 39(29,50) 46/145: 32(25,39) 18/80: 23(15,32) 0.07
Vasopressors for above scenario 129/307: 42(37,48) 36/82: 48(37,59) 68/145: 47(38,54) 25/80: 31(23,41) 0.02
Blood transfusion for refractory shock with
decreased hematocrit
143/300: 46(40,51) 46/79: 53(42,64) 63/139: 46(38,53) 34/82: 41(32,52) 0.33
Vasopressors for last scenario 79/300: 27(22,32) 17/79: 22(14,33) 45/139: 33(26,40) 17/82: 21(14,30) 0.06
Actual Practice (% who never give):
Corticosteroid 389/666: 57(53,61) 92/127: 72(64,80) 148/266: 56(50,61) 149/273: 55(49,60) 0.006
Prophylactic platelet transfusion 90/152: 57(49,64) 34/48: 70(56,81) 43/83: 51(41,61) 13/21: 62(42,79) 0.14
Intravenous immunoglobulin 322/351: 92(89,94) 80/84: 97(93,99) 134/156: 86(80,91) 108/111: 97(92,99) ,0.001
*Percentages incorporate survey design weights, and thus may not equal the crude proportions.
doi:10.1371/journal.pntd.0003192.t004
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dengue and timely initiation of supportive care is the cornerstone
of dengue clinical management. Survey respondents, regardless of
their level of training, were largely unable to identify early signs
of shock and warning signs for severe dengue. Moreover, because
of their lack of knowledge, most respondent’s reported hospital
referral criteria deviated from WHO guidelines. Those guidelines
recommended that dengue patients without bleeding or warning
signs could be monitored at home by family members while
clinicians monitor platelet count and hematocrit as an outpatient.
Suspected dengue patients with any hemorrhagic manifestation
and patients with a platelet count ,100,000 cells per mm3
concurrent with an elevated hematocrit for age and sex were to
be referred to a hospital for further evaluation. Dengue patients
with signs of shock and/or warning signs were to be referred for
inpatient hospitalization. Consistent with these findings fatal case
review studies conducted in Puerto Rico have found missed
opportunities for referral and hospital admission [12,23].
Both the 1997 guidelines and the current 2009 WHO guidelines
have comparable treatment algorithms for the use of intravenous
crystalloids, colloids, and blood transfusions in dengue patients
with refractory shock. Findings from our survey suggest that these
treatment algorithms, especially the use of intravenous colloids for
refractory shock due to severe plasma leakage, may not be as
widely used as should be. In the same year as the survey was
conducted, a medical record review from a case-series of
laboratory-positive fatal dengue cases in Puerto Rico found that
only one patient was given an intravenous colloid solution before
the terminal event even though six of eight case-patients who died
in the hospital had refractory shock [12]. This is noteworthy
because application of the WHO treatment guidelines have been
associated with a reduction in case fatality rates from 10 to less
than 1% among patients with severe dengue [4–8].
Even though WHO guidelines [13,18–20] and a 2006
Cochrane review [24] recommend against the use of corticoste-
roids in patients with dengue, 43% of respondents reported
prescribing corticosteroids, a finding corroborated by the 2007
fatal dengue case-series that found that 55% of fatal laboratory-
positive dengue cases were given a corticosteroid [12]. This
practice also occurs in other dengue endemic countries [25,26].
Reasons given by respondents for use of corticosteroids included
use as an immune modulator given that severe manifestations of
dengue are thought, in part, to be immune mediated (CDC, data
not presented). However, a recent randomized clinical trial
evaluating the early use of oral prednisolone in dengue patients
found treatment to have little impact on the host immune response
[27]. In addition, while the trial was not powered to assess efficacy,
there was no evidence that treatment lead to a reduction in the
severity of plasma leakage, or the development of shock or clinical
bleeding. In short, with no evidence of therapeutic benefit and
multiple potential side effects including hyperglycemia, immuno-
suppression, secondary infections, and gastrointestinal bleeding in
critically ill patients, corticosteroids should not be used to treat
patients with dengue [24,27].
Despite a lack of evidence, many of our survey respondents
reported giving prophylactic platelet transfusions to their
patients with dengue; a practice that may be relatively
common among physicians in dengue endemic countries
[25,28]. Several studies have found no correlation between
platelet count and bleeding or bleeding severity in patients
with dengue, and when given, prophylactic platelet transfu-
sions do not expedite platelet recovery [29–32]. Moreover, the
practice is costly and may contribute to fluid overload and the
development of pulmonary edema resulting in increased
hospital stays among dengue patients. A recent randomized
control trial suggested that prophylactic platelet transfusions
have no therapeutic benefit when given to patients with dengue
and they may be associated with adverse outcomes including
transfusion reactions [33]. A clinical trial is currently ongoing
to further evaluate the use of prophylactic platelet transfusions
among patients with dengue (ClinicalTrials.gov identifier
NCT01030211).
Although these findings contribute to our understanding of the
knowledge and management of dengue in Puerto Rico, our study
has several limitations. First, non-response might have biased the
results [34,35]. Demographic and training characteristics of
respondents and non-respondents were similar in most respects,
though there was somewhat higher response by females, but we do
not expect that this or other differences likely relate to their level of
knowledge and practice. Second, our survey relied on self-reported
practices and the accuracy of this information is not known.
Previous studies suggest that physicians often over state their
compliance with clinical guidelines when compared with chart
review [36,37]. An evaluation is ongoing to confirm actual practice
patterns for hospitalized dengue patients in Puerto Rico. Lastly,
differences in knowledge and practices we found among physician
groups may be explained by non-Board certified physicians having
less contact with severe dengue patients. However, there was no
difference among the groups in the average number of clinical
diagnoses made in the three months before participating in the
survey.
In summary, our survey suggests that despite dengue being
endemic in Puerto Rico for more than 40 years, physicians’
diagnosis and clinical management of dengue in Puerto Rico are
not optimal. As other dengue endemic countries have reported
similar findings, a sustained continuing medical education training
initiative may be necessary to improve case detection and clinical
management even in countries where the disease is common
[25,28]. Findings from this survey were used to develop and
implement a post graduate clinical management course attended
by more than 8,000 physicians licensed to practice in Puerto Rico
in 2010 and create an on-line version of the course that was
released in March of 2014. Further study is needed to determine if
focused training can improve clinical management by minimizing
failed early recognition of severe dengue and delayed initiation of
supportive care that can result in higher rates of medical
complications, longer hospital stays, and increased hospital costs.
An evaluation of the course and its impact on the clinical
management of dengue in Puerto Rico is ongoing.
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